Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma is viewed positively because its 1Q26 update and April PIPE financing materially reduced near-term funding risk, providing $10.0M upfront and up to $60.0M in potential gross proceeds, with management expecting cash runway into 1Q27. The core catalyst is tivoxavir marboxil, which is progressing from an Australia bridging study into an hVIVO human influenza challenge trial after MHRA approval, with the compressed tablet formulation being tested for 28 days of coverage and once-monthly prophylaxis potential. That broader seasonal flu and pandemic-preparedness framing, combined with ratutrelvir’s optionality as a ritonavir-free COVID antiviral, supports an asymmetric thesis where successful clinical data could create meaningful value relative to the current market cap.

Traws Pharma is facing a materially weaker fundamental setup after the 6/12/2026 deferral of tivoxavir marboxil in the Phase 2a human influenza challenge study, which removes the company’s most credible near-term value catalyst and suggests regulator-level concern with the clinical package, likely tied to safety or genotoxicity. The U.S. IND for TXM remains on clinical hold, so the UK pathway was meant to bypass that obstacle, and its setback pushes the lead influenza program back toward additional regulatory work or a backup-candidate strategy. At the same time, ratutrelvir appears de-emphasized, the COVID market has shrunk sharply, and even Paxlovid sales fell to $186M for 1Q26 from $1.2B in 3Q25, leaving the company with reduced visibility and only modest support from collaboration and licensing revenue.